Lineage Cell Therapeutics, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
Lineage Cell Therapeutics, Inc. (LCTX) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $22.00 thousand as of 2023-12-31, per its 10-K filed 2024-03-07.
Discontinued › Notes › Intangible Assets › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2024-03-07
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $22.00K.
- 2023-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $22.00K.
- 2023-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $22.00K.
- 2023-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $22.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2023-12-31 | $22.00K 10-K · filed 2024-03-07 |
| 2023-09-30 | $22.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $22.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $22.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $130.00K 10-K · filed 2023-03-09 |
| 2022-09-30 | $130.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $130.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $130.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $130.00K 10-K · filed 2022-03-10 |
| 2021-09-30 | $130.00K 10-Q · filed 2021-11-10 |
| 2020-12-31 | $210.00K 10-K · filed 2021-03-11 |
| 2019-12-31 | $1.22M 10-K · filed 2020-03-12 |
| 2018-12-31 | $1.91M 10-K · filed 2019-03-14 |
| 2017-12-31 | $2.34M 10-K · filed 2018-03-15 |
| 2016-12-31 | $2.57M 10-K · filed 2017-03-16 |
| 2015-12-31 | $5.26M 10-K · filed 2016-03-15 |
| 2014-12-31 | $5.26M 10-K · filed 2015-03-11 |
| 2013-12-31 | $5.47M 10-K · filed 2014-03-17 |
| 2012-12-31 | $2.57M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |